Eudragit S-100 Surface Engineered Nanostructured Lipid Carriers for Colon Targeting of 5-Fluorouracil: Optimization and In Vitro and In Vivo Characterization
- 12 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in AAPS PharmSciTech
- Vol. 22 (6), 1-15
- https://doi.org/10.1208/s12249-021-02099-3
Abstract
5-Fluorouracil (5-FU) is the most preferred chemotherapeutic agent in the management of colon cancer but is associated with poor therapeutic efficacy and lack of site specificity. Hence, it was aimed to employ Eudragit S100 surface engineered 5-FU nanostructured lipid carriers for the spatial and temporal release of the drug for the treatment of colon cancer. Hot high-pressure homogenization (HPH) technique was employed in the preparation of 5-FU-NLCs. The optimization of 5-FU-NLCs was performed using a Quality by Design (QbD) approach. A 32 factorial design was employed wherein the relationship between independent variables [amount of oleic acid (X1) and concentration of Tween®80 (X2)] and dependent variables [particle size (Y1) and % entrapment efficiency (Y2)] was studied. Optimized 5-FU-NLCs were surface treated to obtain Eudragit S100-coated 5-FU-NLCs (EU-5-FU-NLCs). The evaluation parameters for 5-FU-NLCs and EU-5-FU-NLCs included surface morphology, particle size, PDI, and zeta potential. In vitro release from EU-5-FU-NLCs revealed a selective and controlled 5-FU release in the colonic region for 24 h. In vitro cytotoxicity (MTT assay) was performed against Caco-2 cancer cells, wherein EU-5-FU-NLCs exhibited a 2-fold greater cytotoxic potential in comparison to a 5-FU solution (5-FU-DS). Oral administration of EU-5-FU-NLCs in Albino Wistar rats depicted a higher Cmax (2.54 folds) and AUC (11 folds) as well as prolonged Tmax (16 folds) and MRT (4.32 folds) compared to 5-FU-DS confirming higher bioavailability along with the spatial and temporal release in the colonic region. Thus, a multifaceted strategy involving abridgement of nanotechnology along with surface engineering is introduced for effective chemotherapy of colon cancer via oral administration of 5-FU with uncompromised safety and higher efficacy. Graphical abstractKeywords
This publication has 51 references indexed in Scilit:
- Optimization of LDL targeted nanostructured lipid carriers of 5-FU by a full factorial designIbnosina Journal of Medicine and Biomedical Sciences, 2012
- Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasisInternational Journal of Pharmaceutics, 2010
- Release Kinetic Studies of Aspirin Microcapsules from Ethyl Cellulose, Cellulose Acetate Phthalate and their Mixtures by Emulsion Solvent Evaporation MethodScientia Pharmaceutica, 2010
- A stability-indicating RP-HPLC assay method for 5-fluorouracilIndian Journal of Pharmaceutical Sciences, 2009
- 5-Fluorouracil: Mechanisms of Resistance and Reversal StrategiesMolecules, 2008
- Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: Ex vivo and in vivo studiesInternational Journal of Pharmaceutics, 2008
- In vitro and in vivo evaluation of methoxy polyethylene glycol–polylactide (MPEG–PLA) nanoparticles for small-molecule drug chemotherapyBiomaterials, 2007
- Observations in simultaneous microencapsulation of 5-fluorouracil and leucovorin for combined pH-dependent releaseEuropean Journal of Pharmaceutics and Biopharmaceutics, 2005
- Safety and Toxicity Analysis of Oxaliplatin Combined With Fluorouracil or as a Single Agent in Patients With Previously Treated Advanced Colorectal CancerJournal of Clinical Oncology, 2003
- First-Pass Metabolism of 5-Fluorouracil in the Perfused Rat Small Intestine.Biological & Pharmaceutical Bulletin, 1998